We have recently shown that intrastriatal injection of recombinant human erythropoietin (EPO) protects dopaminergic (DA) neurons in the substantia nigra (SN) from 6-hydroxydopamine (6-OHDA) toxicity in a rat model of Parkinson's disease. However, systemic administration of EPO did not protect nigral DA neurons, suggesting that the blood-brain barrier limits the passage of EPO protein into the brain. In the present study, we used an adenoassociated viral (AAV) serotype 9 (AAV9) vector to deliver the human EPO gene into the brain of 6-OHDA-lesioned rats. We observed that expression of the human EPO gene was robust and stable in the striatum and the SN for up to 10 weeks. EPO-immunoreactive (IR) cells were widespread throughout the injected striatum, and EPO-IR neurons and fibers were also found in the ipsilateral SN. Enzyme-linked immunosorbent assay and western blot analyses exhibited dramatic levels of EPO protein in the injected striatum. As a result, nigral DA neurons were protected against 6-OHDA-induced toxicity. Amphetamine-induced rotational asymmetry and spontaneous forelimb use asymmetry were both attenuated. Interestingly, we also observed that intrastriatal injection of AAV9-EPO vectors led to increased numbers of red blood cells in peripheral blood. This highlights the importance of using an inducible gene delivery system for EPO gene delivery.
Introduction
Erythropoietin (EPO) is a hematopoietic growth factor that stimulates the production of red blood cells. However, EPO has recently received attention for its neuroprotective effects in the CNS (central nervous system). Accumulating evidence has shown that EPO protein and EPO receptors (EPORs) exist in CNS neurons.
1,2 EPO has been found to protect dopaminergic (DA) neurons from experimental insults and druginduced degeneration, 1, [3] [4] [5] [6] suggesting its therapeutic potential for Parkinson's disease (PD). In our previous study with EPO protein infusions, although intrastriatal delivery was protective, systemic administration of EPO did not protect DA neurons from 6-hydroxydopamine (6-OHDA) toxicity in a rat model of PD. 6 The bloodbrain barrier may therefore limit the passage of EPO protein into the brain, preventing it from reaching a therapeutic level. We hypothesized that in vivo gene delivery may circumvent this limitation and lead to persistent therapeutic protein production in the brain, which is required for treating the chronic pathological processes of PD.
In the present study, we used an adeno-associated viral (AAV) serotype 9 (AAV9) vector to deliver the human EPO gene into the rat brain. A variety of viral vectors, including adenoviral, AAV, herpes simplex viral (HSV) and lentiviral vectors, have been shown to successfully deliver therapeutic genes into the brain in animal models of PD. [7] [8] [9] [10] [11] [12] Among them, AAV vectors are of particular interest because they are non-pathogenic, can transduce non-dividing cells and result in longterm transgene expression. 13, 14 They also cause no detected toxicity and minimal immune responses in transduced regions. 15, 16 Moreover, AAV vectors are FDA (Food and Drug Administration) approved and are currently being used in clinical trials.
14 Numerous studies have shown that recombinant AAV with newer serotypes have improved gene transfer into the brain. [17] [18] [19] [20] AAV9 vectors are of particular interest because of their high gene transfer efficiency in the brain. [18] [19] [20] Adeno-associated virus-mediated EPO gene delivery into skeletal muscle has been previously reported to result in sustained EPO gene expression and systemic delivery of therapeutic protein in mice [21] [22] [23] [24] and nonhuman primates. [25] [26] [27] [28] However, it is not clear whether AAV-mediated EPO gene delivery into the brain can produce sustained EPO gene expression and elicit functional benefits in an animal model of PD. In a gene transfer study with a HSV vector for EPO, Puskovic et al., 11 reported that HSV-mediated delivery of EPO into the brain restored DA function in a MPTP (1-methyl-4-phenyl-1,2,3,6 tetrahydropyridine)-induced mouse model of PD. The goal of this study was to determine whether recombinant AAV9-mediated EPO gene delivery into the striatum before 6-OHDA lesioning could protect nigral DA neurons against 6-OHDA-induced toxicity, thereby improving the survival of nigral DA neurons and behavioral performance in a rat model of PD. The results in the present study extended the findings of the EPO HSV vectors in MPTP-treated mice by using an AAV vector for EPO delivery in 6-OHDA-treated rats. We also examined the number of red blood cells in the peripheral blood to test whether functional levels of the expressed EPO could leak out of the brain to stimulate erythropoiesis. We assessed whether the AAV9 EPO vector could be advantageous for long-term expression and neuroprotection to evaluate EPO as a therapeutic agent for PD.
Results

Transgene expression in the rat striatum after AAV9 vector transduction
We generated an AAV9-EPO vector in which EPO gene expression is driven by a hybrid promoter of cytomegalovirus immediate early enhancer and chicken b-actin ( Figure 1a ). An AAV9-green fluorescent protein (GFP) vector was used as a control vector (Figure 1b) . To determine the efficiency of AAV9-mediated transgene expression in the rat striatum, we examined GFP transgene expression in the rat striatum in the AAV9-GFP+6-OHDA group, and EPO transgene expression in the rat striatum in the AAV9-EPO+6-OHDA group at two time points (3 and 10 weeks after viral injection). As the 6-OHDA lesion was created at 3 weeks after viral injection, it was important to determine whether transgenes were efficiently expressed and transgene products were sufficiently produced at this interval. In rats that received an injection of AAV9-GFP vectors to the striatum, one AAV9-GFP injection (2 ml, 1.0 Â 10 13 vector genomes, vg ml À1 ) resulted in widespread GFP gene expression (Figure 1c ). In addition, GFP immunoreactivity was found in the substantia nigra (SN), primarily in the SN pars reticulata (SNpr), ipsilateral to the viral injection side (Figure 1d ). In rats that received AAV9-EPO injections, intense EPO immunoreactivity was found in the injected striatum ( Figure 1e ) and in the ipsilateral SN (Figure 1f ). ELISA for EPO showed that there were significantly higher levels of EPO in the ipsilateral striatum (2232 ± 207 mU ml À1 , n ¼ 5) than in the contralateral striatum (28 ± 10 mU ml
À1
, n ¼ 5) of AAV9-EPO-injected rats, or in the ipsilateral striatum (0±0 mU ml
, n ¼ 5) of AAV9-GFP-injected rats (**Po0.01) (Figure 1g ).
Similar patterns of GFP and EPO expression were also seen in the injected striatum (Figures 2a, b, 3a and d ) and in the ipsilateral SN (Figures 2c, 3b and e) 10 weeks after viral injection and 7 weeks after 6-OHDA lesioning.
To examine whether neurons in the striatum and in the SN express EPORs, brain sections from different groups and different time points were immunostained for EPORs (Figures 2d and e) . Double fluorescent immunostaining showed that EPORs and NeuN, a marker of neuronal cells, were co-localized in the vast majority of neurons in the ipsilateral striatum (Figure 2d) , and EPOR and tyrosine hydroxylase were co-localized in the vast majority of neurons in the ipsilateral SN (Figure 2e ) 10 weeks after AAV9-EPO viral injection. For SN neurons, EPORs appeared to be abundantly presented in the nuclear region. EPORs were also expressed in majority of showing the amount of EPO protein in the ipsilateral striatum of AAV9-GFP-injected rats (GFP-ipsi, n ¼ 5), and in the contralateral (EPO-contra, n ¼ 5) and ipsilateral striatum (EPO-ipsi, n ¼ 5) of AAV9-EPO-injected rats. The data are presented as mean values+s.e.m. One-factor ANOVA (analysis of variance) with post hoc comparison was applied. **Po0.01 versus the ipsilateral striatum of AAV9-GFP-injected rats and the contralateral striatum of AAV9-EPO-injected rats, respectively. Striatal tissue was prepared from the whole striatum of the AAV9-EPO-or AAV9-GFPinjected rats.
Erythropoietin gene transfer into the rat brain Y-Q Xue et al neurons in the contralateral striatum and in the contralateral SN in the different groups at different time points (data not shown). GFP-expressing cells were distributed throughout the injected striatum (Figures 2a  and 3a) . Morphologically, GFP-expressing cells resembled neurons. Double fluorescent immunostaining showed that GFP and NeuN were co-localized in the vast majority of GFP-immunoreactive (IR) cells (accounted for 90±2% of GFP-IR cells) (Figure 3a) . GFP immunoreactivity was also found in the SN, primarily in the SNpr, ipsilateral to the 6-OHDA-lesioned side ( Figure  3b ). TH-IR neurons were present in the ipsilateral SN pars compacta (SNpc) (Figure 3b) . However, such cells had fewer TH-IR processes when compared with TH-IR neurons in the AAV9-EPO+6-OHDA group, indicating neuronal damage in the AAV9-GFP+6-OHDA group (Figures 3b and e) . A few TH-IR neurons in the ipsilateral SNpc were also labeled with GFP (Figure 3b ), indicating retrograde transduction of SN neurons after gene delivery to the striatum. No GFP-IR cells in the injected striatum were found to be labeled with GFAP (glial fibrillary acidic protein), a marker of astrocytes ( Figure  3c ). In rats that received AAV9-EPO injections, widespread EPO-IR cells were found in the injected striatum ( Figure 3d ). EPO-IR cells resembled neurons. Double fluorescent immunostaining showed that the vast majority of EPO-IR cells were co-labeled with NeuN (accounted for 93 ± 1% of EPO-IR cells) (Figure 3d ). EPO immunoreactivity was also found in the SN, primarily in the SNpr, ipsilateral to the 6-OHDA-lesioned side ( Figure  3e) . A large number of TH-IR neurons and fibers in the ipsilateral SNpc were preserved, and the majority of TH-IR neurons were co-labeled with EPO ( Figure 3e ). EPO protein appeared to be present in the peri-nuclear regions. ELISA for EPO indicated that there were significantly higher levels of EPO in the ipsilateral , n ¼ 5) than in the contralateral striatum (17±5 mU ml
, n ¼ 5) of rats in the AAV9-EPO+6-OHDA group, or in the ipsilateral striatum (0±0 mU ml
, n ¼ 5) of rats in the AAV9-GFP+6-OHDA group (**Po0.01) (Figure 3f ). No significant difference was found in the levels of EPO in the injected striatum between the 3 and 10-week time points for rats in the AAV9-EPO+6-OHDA group (P40.05). Western blots confirmed that significant levels of EPO protein were produced in the ipsilateral striatum of rats in the AAV9-EPO+6-OHDA group. In contrast, EPO protein was not detected in the contralateral striatum (Figure 3g ). These results suggested that levels of endogenous EPO in the striatum , and in the contralateral (EPO-contra, n ¼ 5) and ipsilateral striatum (EPOipsi, n ¼ 5) of rats in the AAV9-EPO+6-OHDA group. The data are presented as mean values+s.e.m. One-factor ANOVA (analysis of variance) with post hoc comparison was applied. **Po0.01 versus the ipsilateral striatum of rats in the AAV9-GFP+6-OHDA group and the contralateral striatum of the AAV9-EPO+6-OHDA group, respectively. (g) Western blots showing the amount of EPO protein in the striatum of two representative rats (number 3 and 7). 3L and 7L depict the left striatal tissue, and 3R and 7R represent the right injected striatal tissue. Striatal tissue was prepared from the whole striatum of rats.
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Effect of AAV9-mediated EPO gene delivery on behavioral performance Rotational behavior. A two-factor ANOVA (analysis of variance) did not reveal a significant group Â time interaction of the net rotational scores over the testing period (P40.05). Intrastriatal injections of AAV9-EPO resulted in a significant reduction of the number of Damphetamine-induced rotations for hemiparkinsonian rats in the AAV9-EPO+6-OHDA group (n ¼ 7) 4 (6 ± 2 net rotation min
) and 6 (4±2) weeks after 6-OHDA lesioning when compared with rats in the AAV9-GFP+6-OHDA group (16±3 at 4 weeks, and 12±3 at 6 weeks, n ¼ 6) or in the saline+6-OHDA group (11 ± 1 at 4 weeks and 13±3 at 6 weeks, n ¼ 7) (*Po0.05) (Figure 4a) . However, the mean value for D-amphetamine-induced rotational asymmetry in the AAV9-GFP+6-OHDA group (19 ± 2) was significantly greater than in the AAV9-EPO+6-OHDA group (9±3) or in saline+6-OHDA group (10 ± 1) 2 weeks after 6-OHDA lesioning (*Po0.05). It is known that GFP is a relatively stable protein, which can accumulate inside cells, and thus is often toxic to cells. We previously showed that the high levels of GFP derived from AAV8 were neurotoxic to dopamine neurons in the SN. 29 In the present study, overexpression of GFP by AAV9-GFP vectors in the virally injected striatum may render nigral DA neurons more vulnerable to 6-OHDA lesioning. As a result, the magnitude of amphetamine-induced rotational asymmetry is greater in the AAV9-GFP+6-OHDA group than in the AAV9-EPO+6-OHDA group or in the saline+6-OHDA group.
Intrastriatal injections of AAV9-EPO alone did not lead to D-amphetamine-induced rotational asymmetry in unlesioned rats (0 ± 0, n ¼ 5).
Forelimb use. At 10 weeks after viral injection and 7 weeks after 6-OHDA injection, the percentages of spontaneous forelimb use ipsilateral to the 6-OHDA lesion side were significantly higher in the AAV9-GFP+6-OHDA group (80 ± 6%, n ¼ 6) and in the saline+6-OHDA group (77 ± 10%, n ¼ 7) than in the AAV9-EPO+6-OHDA (33±10%, n ¼ 7), AAV9-EPO alone (34±7%, n ¼ 5) or normal control groups (36 ± 6%, n ¼ 7) (**Po0.01) (Figure 4b ). These data suggest that rats in both the AAV9-GFP+6-OHDA and the saline+6-OHDA groups use the unaffected ipsilateral forelimbs more than the affected contralateral forelimbs in the cylinder test, and the EPO gene transfer preserved the use of the affected contralateral forelimb relative to the GFP vector or saline treatments. The percentage of use of both forelimbs was significantly greater in the AAV9-EPO+6-OHDA group (41±9%, n ¼ 7) than in the AAV9-GFP+6-OHDA group (8 ± 7%, n ¼ 6) or in the saline+6-OHDA group (13 ± 7%, n ¼ 7) (*Po0.05), and the percentage of forelimb use for both forelimbs was significantly greater in the AAV9-EPO alone group (36±13%, n ¼ 5) than in the AAV9-GFP+6-OHDA group (8 ± 7%, n ¼ 6) (*Po0.05), which also indicated preservation of contralateral forelimb use by EPO.
Effect of EPO gene delivery on the survival of DA neurons and their axons after 6-OHDA lesioning TH-immunoreactivity in the striatum. 
and AAV9-EPO alone (n ¼ 5) groups. Rotational behavioral tests were performed 2, 4 and 6 weeks after 6-OHDA injection. Rotational asymmetry was recorded for 90 min using an automated rotometer system after rats were injected i.p. with 5 mg kg À1 D-amphetamine. The data are presented as mean values + s.e.m. Two-factor ANOVA (analysis of variance) and one-factor ANOVA with post hoc comparison were applied. *Po0.05 versus the other two groups for the top three groups (AAV9-EPO+6-OHDA, AAV9-GFP+6-OHDA and saline+6-OHDA) at the same time points, respectively. Arrows point to the time points when rats received intrastriatal injections of viral vectors and 6-OHDA. (b) The diagram summarizes the percentage of spontaneous forelimb use contralateral and ipsilateral to the 6-OHDA lesion side, or both forelimbs in the AAV9-EPO+6-OHDA (n ¼ 7), AAV9-GFP+6-OHDA (n ¼ 6), saline+6-OHDA (n ¼ 7), AAV9-EPO alone (n ¼ 5) and normal (n ¼ 7) groups 7 weeks after 6-OHDA injection. The data are presented as mean values+s.e.m. One-factor ANOVA with post hoc comparison was applied. **Po0.01 versus the AAV9-EPO+6-OHDA, AAV9-EPO alone and normal groups. *Po0.05 versus the saline+6-OHDA and AAV9-GFP+6-OHDA groups. GFP, green fluorescent protein.
Erythropoietin gene transfer into the rat brain Y-Q Xue et al in the AAV9-EPO+6-OHDA group 10 weeks after viral injection and 7 weeks after 6-OHDA lesioning. A reduction in TH-immunoreactivity was observed only in the areas surrounding the 6-OHDA needle tracks in AAV9-EPO+6-OHDA-treated rats (Figure 5a ). The optical density of TH immunostaining in the injected striatum was 52±6% of the optical density seen in the contralateral striatum (internal control) of rats in the AAV9-EPO+6-OHDA group (n ¼ 7), which was significantly greater than that in the AAV9-GFP+6-OHDA group (24±5%, n ¼ 6) or in the saline+6-OHDA (8±3%, n ¼ 7) group (**Po0.01) (Figures 5a-c and i) , but less than that in the AAV9-EPO alone (100±3%, n ¼ 5) group (**Po0.01) (Figures 5g and i) .
TH-IR cell counts in the SN. There was intense immunostaining for TH-IR cell bodies in the ipsilateral SNpc of rats in the AAV9-EPO+6-OHDA group 10 weeks after viral injection and 7 weeks after 6-OHDA injection (Figure 5d ). The number of TH-IR cells in the ipsilateral SN was 67 ± 7% of the number in the contralateral SN (internal control) of rats in the AAV9-EPO+6-OHDA group (n ¼ 7), which was significantly greater than that in the AAV9-GFP+6-OHDA group (44±4%, n ¼ 6) or in the saline+6-OHDA (40 ± 8%, n ¼ 7) group (*Po0.05) (Figures 5d-f and j) , but less than that in the AAV9-EPO alone (92 ± 13%, n ¼ 5) group (**Po0.01) (Figures 5h and j) . TH-IR neurons in the ipsilateral SN of rats in the AAV9-EPO+6-OHDA and AAV9-EPO alone groups also sent extensive TH-IR fibers from the SNpc into the SNpr (Figures 5d and h) .
Effect of EPO gene delivery into the brain on the number of red blood cells in peripheral blood
To examine whether intrastriatal injections of AAV9-EPO could have systemic effects on erythropoiesis, the number of red blood cells in peripheral blood was measured. The number of red blood cells in peripheral blood was significantly greater in the AAV9-EPO+ 6-OHDA group (11.1 ± 0.4 million per ml, n ¼ 7, **Po0.01) and in the AAV9-EPO alone group (10.6±0.8 million per ml, n ¼ 5, # Po0.05) than in the AAV9-GFP+ 6-OHDA group (8.5±0.7 million per ml, n ¼ 6) or in the saline+6-OHDA group (8.2 ± 0.2 million per ml, n ¼ 5) 10 weeks after viral injection ( Figure 6 ).
Discussion
We show that AAV9 vectors can efficiently deliver the human EPO gene into the rat brain, leading to production Intrastriatal administration of AAV9-EPO vectors 3 weeks before the intrastriatal injections of 6-OHDA attenuates both the dopamine depletion in the injected striatum and the degeneration of TH-IR neurons in the ipsilateral SN of the rats. As a result, amphetamineinduced rotational asymmetry and spontaneous forelimb use asymmetry were both reduced. AAV9-mediated human EPO gene expression is stable in the rat brain for up to 10 weeks. Moreover, intrastriatal administration of AAV9-EPO led to an increase in the number of red blood cells in peripheral blood. This highlights the importance of the use of a mutated EPO gene encoding non-hematopoietic EPO or the introduction of an inducible gene delivery system to avoid any adverse side effects. [23] [24] [25] 27, 30, 31 The positive effects of EPO gene transfer that we observed on preservation of SN DA neurons and their axons, and protection from behavioral abnormalities induced by 6-OHDA support further development of EPO as a therapeutic target for PD. Our previous study with EPO protein administration showed that systemic administration of EPO protein was insufficient for DA neuroprotection in the brain. 6 In contrast, the EPO gene transfer approach used here was successful for long-term expression and neuroprotection derived from a single surgical treatment. The AAV9 vector produced widespread neuronal expression of either EPO or GFP transgenes in the striatum, which recapitulated the high-efficiency neuronal transduction observed previously with this vector in the rat hippocampus or SN. 19, 20 The expression seemed to be stable between 3 and 10 weeks after gene transfer. In addition to the widespread striatal transduction, either the expressed EPO or GFP was detected in the SNpr, an anterograde terminal area of striatal output neurons, and for EPO, expression was observed in DA neuronal perikarya in the SNpc. We assume that the EPO expression pattern in the SNpc was a result of retrograde transduction by infection of nigrostriatal axons, although we cannot rule out that the expressed EPO protein itself was retrogradely transported. Transduction profiles of the AAV9 vectors after striatal injections were similar to previous findings using AAV2 or AAV5 vectors. 32 It has been suggested that EPO exerts its neuroprotective effects on CNS neurons through multiple mechanisms, including anti-apoptosis, 5, 33 anti-inflammation, 34 inhibition of glutamate release, inhibition of reactive oxygen species formation, 35 activation of Akt/ protein kinase B through the phosphoinositide 3-kinase pathway, 5 and activation of Janus kinase-2 and nuclear factor-kB signaling pathways. 36 We have recently showed that intrastriatal administration of EPO protects nigral DA neurons from cell death induced by 6-OHDA in part through an anti-inflammatory mechanism. 6 In the present study, the evidence of EPO protein accumulation in the ipsilateral SN induced by AAV9-mediated EPO gene delivery into the striatum highlights the notion that EPO protein protects DA neurons in the SN directly through a receptor-mediated mechanism, as DA neurons have EPORs, 1,2 but does not exclude local antioxidant, anti-apoptotic and anti-inflammatory mechanisms. Indeed, we observed that EPORs are expressed in striatal and SN neurons in the present study (Figures 2d and e) .
Our findings of cellular and behavioral improvements in a rat model of PD, support the results of Puskovic et al., 11 who showed that an HSV vector for EPO restored DA function in an MPTP-induced mouse model of PD. Their study determined that EPO was equally efficacious as glial cell-derived neurotrophic factor, and that the EPO vector could confer neuroprotection even after lesioning. Although our study only attempted gene transfer before the 6-OHDA lesioning, we have shown EPO to be effective in a different rodent species with an alternate DA neurotoxin. The Puskovic et al. study showed elevated levels of EPO protein in the striatum and in the SN 1 week after gene transfer by ELISA, whereas here, we were able to monitor EPO protein expression for an extended 10-week period by immunocytochemistry, ELISA and western blot, and also observed a peripheral EPO effect.
Despite the positive cellular and behavioral effects of the AAV9-EPO vector, the neuroprotection of nigral DA neurons and improvement of behavioral abnormalities was only partial. EPO gene transfer into the brain did not reach the same level of neuroprotection and behavioral improvement as our previous EPO protein study. 6 The lesser effects may reflect the amount of EPO protein present in the striatum upon the introduction of 6-OHDA. In the previous study, an intrastriatal bolus injection of EPO protein (20 units) was carried out, whereas only about 2 units of EPO were detected in the striatum before 6-OHDA lesioning in the present study, as determined by an EPO ELISA. The EPO gene (human EPO gene) used in the present study is xenogeneic to recipient rats. Human EPO protein-induced inflammatory and immune responses may compromise therapeutic efficacy and long-term expression of the EPO gene. The issue of inflammatory and immune responses in AAV9-mediated human EPO gene delivery into the brain should be examined in future studies.
One surprising finding in the present study was that AAV9-mediated EPO gene transfer in the brain exerted .05 versus the AAV9-GFP+6-OHDA and saline+6-OHDA groups; **Po0.01 versus the AAV9-GFP+6-OHDA and saline+6-OHDA groups, respectively. 6-OHDA, 6-hydroxydopamine; GFP, green fluorescent protein.
Erythropoietin gene transfer into the rat brain Y-Q Xue et al systemic effects to enhance erythropoiesis. Previous studies have shown that EPO can pass through the blood-brain barrier after intravenous administration. 37, 38 However, we believe this to be the first example of transgene-encoded EPO passing through the bloodbrain barrier from the brain into blood circulation. We speculate that EPO encoded by the EPO gene in the striatum can pass through the blood-brain barrier into the circulation, stimulating hematopoietic stem cells in bone marrow to produce more red blood cells in peripheral blood. Less likely is the possibility that AAV9-EPO vectors could leak along the needle track outside the skull, leading to EPO gene transduction of muscle surrounding the burr hole and systemic delivery of EPO protein. Continued production of EPO by an AAV vector with a constitutive promoter, therefore, raises safety concerns. Excessive levels of EPO could induce side effects such as polycythemia and thrombosis. These possible side effects of EPO expression underscore the importance of using a mutated EPO gene encoding non-hematopoietic EPO and introducing an EPO gene regulatory system. Carbamylated EPO has recently been developed and characterized. 31 Although carbamylated EPO does not show any hematopoietic activity by binding to the EPOR, it has been found to possess a broad spectrum of neuroprotective activities, as shown in animal models of cerebral ischemia, 31, 39 spinal cord injury 40, 41 and experimental autoimmune encephalomyelitis. 37 In previous studies, controlled EPO expression after AAV-mediated gene transfer to muscle has been achieved with both the tetracycline- 24, 30 and the rapamycin-regulated systems. 23, 25, 27 Future studies will be aimed at the development of an inducible AAV9-EPO gene transfer system. Although the peripheral side effect was an undesired outcome in the present study, at the least it unequivocally showed that the vector-derived EPO was biologically active.
In summary, although our study shows that intrastriatal administration of AAV9-EPO vectors before intrastriatal injection of 6-OHDA protects nigral DA neurons from 6-OHDA-induced neurodegeneration, several improvements in the model are needed, including more complete neuroprotection, regulated transgene expression and avoidance of the peripheral side effect. In addition, further study is needed to examine whether delayed delivery of AAV9-EPO into the striatum prevents nigral neurodegeneration and promotes functional recovery in a rat model of PD. It should be cautioned that when an increased dose of virus is applied to enhance therapeutic efficacy, toxicity and side effects of the virus must also be considered. A dosedependent study is therefore warranted to determine the correlation between the efficacy and toxicity.
Materials and methods
Experimental design
Young adult female Sprague-Dawley rats (Charles River Laboratories, Inc., Wilmington, MA, USA), weighing 225-250 g at the beginning of the experiment were housed under a 12-h light and 12-h dark cycle with ad libitum access to food and water in the Animal Core Facility of LSU Health Sciences Center, Shreveport, USA. All animal procedures were performed following the National Institutes of Health Guide for the Care and Use of Laboratory Animals and were approved by the Animal Use and Care Committee of the LSU Health Sciences Center.
Rats were assigned into the five groups used in the experiments. Group 1 (n ¼ 18, denoted AAV9-EPO+ 6-OHDA): rats received an injection of AAV9-EPO into the right striatum, and an injection of 6-OHDA (Sigma-Aldrich, St Louis, MO, USA) in the same side 3 weeks later. Group 2 (n ¼ 18, AAV9-GFP+6-OHDA): rats received an injection of AAV9-GFP into the right striatum, and an injection of 6-OHDA in the same side 3 weeks later. Group 3 (n ¼ 7, saline+6-OHDA): rats received an injection of saline into the right striatum, and then an injection of 6-OHDA in the same side 3 weeks later. Group 4 (n ¼ 5, AAV9-EPO alone): rats received only an injection of AAV9-EPO into the right striatum. Group 5 (n ¼ 7, Normal): rats did not receive any intrastriatal injections. D-amphetamine (Sigma-Aldrich)-induced rotational asymmetry was examined 3 weeks after viral injection, and 2, 4 and 6 weeks after 6-OHDA lesioning. Spontaneous forelimb use of the rats was examined 7 weeks after 6-OHDA lesioning. At the end of the experiment, all rats were sacrificed and brain sections were prepared for immunocytochemistry. The number of DA neurons in the SN was examined by counting TH-IR cells. Striatal denervation was examined by evaluating the optical density of TH-IR fibers in the striatum. To confirm the presence of EPO protein encoded by the human EPO gene in the striatum and the SN, brain sections containing the striatum and the SN were immunocytochemically processed for EPO. To determine the cell types of virally transduced cells, double labeling was performed for brain sections. To determine levels of EPO protein in the striatum, striatal tissue from both sides was prepared for EPO ELISA from Groups 1 and 2 at 3 and 10 weeks after viral injection (five rats for each group and each time point).
DNA and AAV9 production
The human EPO DNA was obtained from pCR4-TOPO vectors (ATCC, Manassas, VA, USA) and subcloned into an AAV expression plasmid using the EcoR1 enzyme. The expression cassette was flanked with AAV2 terminal repeats and cross-packaged into recombinant AAV9. The hybrid cytomegalovirus immediate early enhancer/ chicken b-actin promoter was used to drive expression. AAV9 vectors for either EPO or the control GFP were constructed as previously described. 42 Human embryonic kidney 293-T cells were co-transduced with either the EPO or the GFP plasmid along with the two packaging plasmids needed to make AAV9. The cell lysate was applied to a discontinuous gradient of iodixanol (OptiPrep, Greiner Bio-One, Longwood, FL, USA) and centrifuged. The AAV was then removed, diluted twofold with lactated Ringer's solution (Baxter, Deerfield, IL, USA) and then washed and concentrated by Millipore (Billerica, MA, USA) Biomax 100 Ultrafree-15 units. The final stocks were sterilized by Millipore Millex-GV syringe filters into low adhesion tubes (USA Scientific, Ocala, FL, USA). Vectors were aliquoted and stored frozen. Encapsidated genome copies were titered by dot blot. The titer of the AAV9 EPO was 5.9 Â 10
13
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À1
. Equal dose comparisons were made by normalizing titers with the diluent, lactated Ringer's solution.
Viral injections
A total of 2 ml of viral vectors (AAV9-EPO or AAV9-GFP at an equal dose of 10 13 vg ml
À1
) or saline were injected unilaterally into the striatum of equithesin (3 ml kg À1 , i.p.) anesthetized rats fixed in a Kopf stereotaxic frame using a 10 ml Hamilton microsyringe (Hamilton Co., Reno, NV, USA) fitted with a steel cannula. Injections were made at the following stereotaxic coordinates: 1.0 mm rostral to bregma; 3.0 mm lateral to the midline; 4.5 mm ventral to the dura, with tooth bar set at zero. The microinjections were carried out at a rate of 0.25 ml min À1 . After injection, the cannula remained in situ for an additional 4 min before being withdrawn.
6-OHDA lesions
Intrastriatal injections of 6-OHDA were performed as described previously. 43 At 3 weeks after virus or saline injection, 15 mg of 6-OHDA dissolved in 3 ml of 1 mg ml À1 ascorbate-saline were injected into the striatum of equithesin (3 ml kg À1 , i.p.) anesthetized rats at the following stereotaxic coordinates: 0 mm rostral to bregma; 3.0 mm lateral to the midline; 5.0 mm ventral to the dura, with the tooth bar set at zero. The microinjections were carried out at a rate of 0.25 ml min
À1
. After injection, the cannula remained in situ for an additional 4 min before being withdrawn.
Behavioral analysis Rotational asymmetry. Rats were injected i.p. with 5 mg kg À1 D-amphetamine and rotational asymmetry was monitored for 90 min using an automated rotometer system (Rota-count B, Columbus Instruments, Columbus, OH, USA). 44 Net rotational asymmetry score is expressed as the number of 3601 turns per min. Rotation toward the lesioned side was considered to be positive.
Cylinder test. To assess forelimb use asymmetry during spontaneous explorative activity along a cylinder wall, a cylinder test was performed in a transparent cylinder (20 cm diameter and 30 cm height) as previously reported. 45 Briefly, simultaneous or independent use of forelimbs to contact the wall during rearing was examined 10 times.
EPO ELISA and western blot EPO ELISA. Rat striatal tissue was freshly prepared for EPO ELISA according to the manufacturer's instructions (MD Biosciences, St Paul, MN, USA). Briefly, rats were anesthetized with equithesin (3 ml kg À1 , i.p.), and striatal tissue was dissected from the rat brains (both the ipsilateral and contralateral striatum). Striatal tissue was homogenized using sonication, and the cell lysate was prepared using T-PER tissue protein extraction reagent (Thermo Scientific, Waltham, MA, USA) for EPO ELISA.
Western blot analysis. The cell lysate of striatal tissue was also used for western blot for detecting EPO. Protein concentration was determined by bicinchoninic acid assay with bovine serum albumin as standard (Pierce, Rockford, IL, USA). Equivalent amounts of protein were separated on 12% sodium dodecyl sulfate polyacrylamide gel and transferred on to polyvinylidene difluoride membranes (Millipore, Bedford, MA, USA). Membranes were incubated with phosphate-buffered saline (PBS) containing 0.05% Tween 20 and 5% non-fat dry milk to block non-specific binding and were incubated with a primary antibody against human EPO (rabbit polyclonal antibody, 1:1000, Santa Cruz Biotechnology Inc, Santa Cruz, CA, USA), then with a secondary antibody conjugated to horseradish peroxidase (donkey antirabbit polyclonal antibody, 1:5000, Jackson ImmunoResearch Laboratories Inc, West Grove, PA, USA). To check the amount of protein loaded, the immunoblots were treated with stripping solution (62.5 mM Tris buffer, pH 6.7, containing 2% sodium dodecyl sulfate and 100 mM bmercaptoethanol) for 30 min at 50 1C and incubated with a primary antibody against glyceraldehyde-3-phosphate dehydrogenase (mouse monoclonal anti-GAPDH, 1:1000, Chemicon International, Temecula, CA, USA) followed by horseradish peroxidase-coupled goat anti-mouse IgG (Pierce). IR bands were visualized by using Renaissance chemiluminescence reagent (Perkin-Elmer Life Science, Waltham, MA, USA).
for 1 h and then incubated over night with primary antibody diluted in blocking solution. After rinsing in PBS, the sections were incubated with cyanine-conjugated secondary antibodies for 2 h in the dark. Cell nuclei were counterstained with DAPI (4 0 ,6-diamidino-2-phenylindole) nuclear stain (1:4000, Sigma). Sections were then mounted on superfrost microscope slides (Fisher Scientific), and cover-slipped using water soluble mountant, AquaPoly/Mount (Polysciences Inc, Warrington, PA, USA). The primary antibodies were mouse anti-TH (1:500, Sigma), rabbit anti-GFP (1:200, Santa Cruz Biotechnology Inc), rabbit anti-EPO (1:200, Santa Cruz Biotechnology Inc), rabbit anti-EPO receptor (M-20, 1:200, Santa Cruz Biotechnology Inc), mouse anti-NeuN (1:400, Chemicon) and mouse anti-GFAP (1:500, Sigma). Secondary antibodies were Cy2-goat anti-mouse, Cy2-goat anti-rabbit, Cy3-goat anti-mouse and Cy3-goat antirabbit (all 1:200, Jackson Laboratories). To evaluate the specificity of immunostaining, normal mouse serum was used instead of a primary antibody on selected brain sections, or primary antibodies were omitted during the immunostaining as a negative control.
Morphological assessment
Striatal and nigral sections processed for TH-and EPO immunostaining were examined and imaged under a Nikon light microscope (Nikon, Tokyo, Japan) with bright-field illumination. Fluorescently labeled sections were examined and imaged using a Nikon Eclipse (TE2000) inverted fluorescence microscope (ECLIPSE TE2000-s, Nikon), or were examined using a confocal laser-scanning microscope (NLO DIRECT COUPLING, LSM 510, Carl Zeiss Inc, Oberkochen, Germany). To examine the percentages of regional neurons that were IR for EPO or GFP in each group, double fluorescent immunostained brain sections containing clear needle tracks were selected from each rat in the AAV9-EPO+6-OHDA and AAV9-GFP+6-OHDA groups. Eight confocol images were randomly prepared from viral transduction areas of each brain section, and cells that were single and double labeled for EPO and NeuN or for GFP and NeuN were analyzed using ImageJ (Version 1.42, NIH Image, Bethesda, MD, USA).
Stereological estimates of TH-IR neurons in the SN. Sections were examined under a Zeiss light microscope (Carl Zeiss) with bright-field illumination in a blinded manner. The original coding of the slides, which indicated treatment groups, was covered by opaque tape and the slides were re-numbered. After evaluation, the original codes were revealed. TH-IR neurons in the SNpc were examined using unbiased stereology (the MicroBrightfield Inc system, Williston, VT, USA), as described previously. 20 Five sections evenly spaced throughout the rostral SNpc structure (from 5.0 to 6.0 posterior to Bregma) were analyzed for each probe. Optical dissectors were 50 Â 50 Â 16 mm cubes spaced in a systematic random manner 150 Â 150 mm apart and offset 2 mm from the section surface. The fractionator sampling was optimized to yield about 100 counted cells per animal for Gundersen error coefficients o0.15.
Densitometric analysis. The optical densities of THimmunostained sections were analyzed using a computer-assisted image analysis system as described previously. 47 All TH-immunostained sections (12-13 sections per rat) were scanned using a Canon scanner (Canon Inc, Tokyo, Japan). For each section, the right or the left striatum was first manually delineated on the screen and the optical density was assessed using NIH image software (Scion Image, Beta 4.0.2, NIH Image). To estimate the TH-immunostaining density, the optical density readings were corrected for non-specific background density, as measured from the cerebral cortex. The data are presented as ratios to the intact side.
Statistical analysis
Data are presented as means±standard error of the mean (s.e.m). A two-factor ANOVA with repeated measures was used to analyze data for rotational asymmetry for time and treatment effects. A one-factor ANOVA followed by Fisher's post hoc test was used to compare the cell counts, the optical density and the behavioral changes between groups. A paired Student's t-test was used to compare the levels of EPO protein in the injected striatum between two time points. Statistical significance was defined at Po0.05.
